80 Evaluation of the trusight oncology 500 assay for routine clinical testing of tumor mutational burden (TMB) and clinical utility for predicting response to pembrolizumab

Abstract

BackgroundVarious biomarkers have been investigated for their ability to identify patients more likely to respond to immunotherapy. Recently, the PD-1 inhibitor pembrolizumab was approved by the FDA for treating patients...